News articles about Abaxis (NASDAQ:ABAX) have trended somewhat positive on Saturday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abaxis earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.7908162374047 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
Shares of Abaxis (ABAX) traded up $0.16 during trading on Friday, hitting $62.44. The company’s stock had a trading volume of 235,965 shares, compared to its average volume of 171,726. Abaxis has a one year low of $43.66 and a one year high of $62.98. The stock has a market cap of $1,420.00, a price-to-earnings ratio of 52.03 and a beta of 0.86.
Abaxis (NASDAQ:ABAX) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. The business had revenue of $58.90 million for the quarter, compared to analyst estimates of $60.85 million. Abaxis had a return on equity of 10.18% and a net margin of 11.98%. The business’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the company posted $0.34 EPS. equities research analysts expect that Abaxis will post 1.11 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, December 1st were given a $0.16 dividend. This is a positive change from Abaxis’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 1.02%. The ex-dividend date of this dividend was Thursday, November 30th. Abaxis’s dividend payout ratio (DPR) is 53.33%.
Abaxis declared that its Board of Directors has authorized a stock repurchase program on Tuesday, October 24th that permits the company to repurchase $21.00 million in outstanding shares. This repurchase authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.
A number of research firms recently weighed in on ABAX. Zacks Investment Research cut Abaxis from a “hold” rating to a “sell” rating in a report on Monday, January 8th. Raymond James Financial upgraded Abaxis from an “underperform” rating to a “market perform” rating in a report on Tuesday. UBS Group upgraded Abaxis from an “underperform” rating to a “market perform” rating in a report on Tuesday. Northcoast Research upgraded Abaxis from a “neutral” rating to a “buy” rating in a report on Friday, January 5th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $47.00 target price (up previously from $46.00) on shares of Abaxis in a report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $47.63.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/01/13/abaxis-abax-given-coverage-optimism-rating-of-0-10.html.
Abaxis Company Profile
Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.
Receive News & Ratings for Abaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abaxis and related companies with MarketBeat.com's FREE daily email newsletter.